Tenosynovial giant cell tumor (TGCT), a rare, nonmalignant tumor, arises from synovium in joints, bursae, and tendon sheaths. The diffuse type often presents aggressively, with high recurrence rates following surgery. The FDA recently approved the first medication for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Individualized treatment plans should be created for patients by evaluating the benefits and risks of surgery and medications, as well as the type and severity of the disease and patient-specific characteristics.
This activity will be delivered via an innovative online platform and led by faculty experts in TGCT using virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions